Psilocybin - Biomind Labs
Latest Information Update: 08 Jan 2022
At a glance
- Originator Biomind Labs
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Anorexia nervosa; Neurological disorders; Substance-related disorders
Most Recent Events
- 03 Sep 2021 Early research in Anorexia nervosa in Canada (unspecified route) (Biomind labs pipeline, September 2021)
- 03 Sep 2021 Early research in Neurological disorders in Canada (unspecified route) (Biomind labs pipeline, September 2021)
- 03 Sep 2021 Early research in Substance-related disorders in Canada (unspecified route) (Biomind labs pipeline, September 2021)